Adjunctive cabergoline therapy of Parkinson's disease: Comparison with placebo and assessment of dose responses and duration of effect

J. Eric Ahlskog, Kathy F. Wright, Manfred D. Muenter, Charles Howard Adler

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Adjunctive cabergoline or placebo, in doses up to 5 mg daily, were administered to Parkinson's disease patients with short-duration levodopa responses in a 6-month double-blind trial. The 13 patients randomized to cabergoline and completing the study had significantly improved Unified Parkinson's Disease Rating Scale (UPDRS) motor scores and timed hand-tapping test scores. Serial measurements on test days documented improved scores: (a) before the first levodopa land cabergoline) dose of the day, (b) at the time of the peak levodopa effect, and (c) at the end of the levodopa response cycle, 5 h after test doses. Continued testing verified that these therapeutic responses were sustained for at least 48 h after the last cabergoline dose. Patients randomized to placebo failed to improve on any of these measures. In a subsequent open-label dose-escalation phase, further improvement was documented as the dosage was gradually raised to 10 mg daily. As in the double-blind phase, levodopa reduction allowed the improvement to occur in the absence of significantly increased dyskinesias. Other side effects were more substantial with higher doses, however, including two of 11 patients with hallucinations and confusion. In summary, adjunctive single- daily-dose cabergoline therapy resulted in long-lasting, dose-related improvement in parkinsonism not seen in patients receiving placebo.

Original languageEnglish (US)
Pages (from-to)202-212
Number of pages11
JournalClinical Neuropharmacology
Volume19
Issue number3
StatePublished - 1996
Externally publishedYes

Fingerprint

Levodopa
Parkinson Disease
Placebos
Therapeutics
Confusion
Hallucinations
Dyskinesias
Parkinsonian Disorders
Hand
cabergoline

Keywords

  • Cabergoline
  • Dopamine agonists
  • Ergolines
  • Parkinson's disease

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Clinical Neurology
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Adjunctive cabergoline therapy of Parkinson's disease : Comparison with placebo and assessment of dose responses and duration of effect. / Ahlskog, J. Eric; Wright, Kathy F.; Muenter, Manfred D.; Adler, Charles Howard.

In: Clinical Neuropharmacology, Vol. 19, No. 3, 1996, p. 202-212.

Research output: Contribution to journalArticle

@article{9393748d4b7b44a58cf1dfe83e66a72b,
title = "Adjunctive cabergoline therapy of Parkinson's disease: Comparison with placebo and assessment of dose responses and duration of effect",
abstract = "Adjunctive cabergoline or placebo, in doses up to 5 mg daily, were administered to Parkinson's disease patients with short-duration levodopa responses in a 6-month double-blind trial. The 13 patients randomized to cabergoline and completing the study had significantly improved Unified Parkinson's Disease Rating Scale (UPDRS) motor scores and timed hand-tapping test scores. Serial measurements on test days documented improved scores: (a) before the first levodopa land cabergoline) dose of the day, (b) at the time of the peak levodopa effect, and (c) at the end of the levodopa response cycle, 5 h after test doses. Continued testing verified that these therapeutic responses were sustained for at least 48 h after the last cabergoline dose. Patients randomized to placebo failed to improve on any of these measures. In a subsequent open-label dose-escalation phase, further improvement was documented as the dosage was gradually raised to 10 mg daily. As in the double-blind phase, levodopa reduction allowed the improvement to occur in the absence of significantly increased dyskinesias. Other side effects were more substantial with higher doses, however, including two of 11 patients with hallucinations and confusion. In summary, adjunctive single- daily-dose cabergoline therapy resulted in long-lasting, dose-related improvement in parkinsonism not seen in patients receiving placebo.",
keywords = "Cabergoline, Dopamine agonists, Ergolines, Parkinson's disease",
author = "Ahlskog, {J. Eric} and Wright, {Kathy F.} and Muenter, {Manfred D.} and Adler, {Charles Howard}",
year = "1996",
language = "English (US)",
volume = "19",
pages = "202--212",
journal = "Clinical Neuropharmacology",
issn = "0362-5664",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Adjunctive cabergoline therapy of Parkinson's disease

T2 - Comparison with placebo and assessment of dose responses and duration of effect

AU - Ahlskog, J. Eric

AU - Wright, Kathy F.

AU - Muenter, Manfred D.

AU - Adler, Charles Howard

PY - 1996

Y1 - 1996

N2 - Adjunctive cabergoline or placebo, in doses up to 5 mg daily, were administered to Parkinson's disease patients with short-duration levodopa responses in a 6-month double-blind trial. The 13 patients randomized to cabergoline and completing the study had significantly improved Unified Parkinson's Disease Rating Scale (UPDRS) motor scores and timed hand-tapping test scores. Serial measurements on test days documented improved scores: (a) before the first levodopa land cabergoline) dose of the day, (b) at the time of the peak levodopa effect, and (c) at the end of the levodopa response cycle, 5 h after test doses. Continued testing verified that these therapeutic responses were sustained for at least 48 h after the last cabergoline dose. Patients randomized to placebo failed to improve on any of these measures. In a subsequent open-label dose-escalation phase, further improvement was documented as the dosage was gradually raised to 10 mg daily. As in the double-blind phase, levodopa reduction allowed the improvement to occur in the absence of significantly increased dyskinesias. Other side effects were more substantial with higher doses, however, including two of 11 patients with hallucinations and confusion. In summary, adjunctive single- daily-dose cabergoline therapy resulted in long-lasting, dose-related improvement in parkinsonism not seen in patients receiving placebo.

AB - Adjunctive cabergoline or placebo, in doses up to 5 mg daily, were administered to Parkinson's disease patients with short-duration levodopa responses in a 6-month double-blind trial. The 13 patients randomized to cabergoline and completing the study had significantly improved Unified Parkinson's Disease Rating Scale (UPDRS) motor scores and timed hand-tapping test scores. Serial measurements on test days documented improved scores: (a) before the first levodopa land cabergoline) dose of the day, (b) at the time of the peak levodopa effect, and (c) at the end of the levodopa response cycle, 5 h after test doses. Continued testing verified that these therapeutic responses were sustained for at least 48 h after the last cabergoline dose. Patients randomized to placebo failed to improve on any of these measures. In a subsequent open-label dose-escalation phase, further improvement was documented as the dosage was gradually raised to 10 mg daily. As in the double-blind phase, levodopa reduction allowed the improvement to occur in the absence of significantly increased dyskinesias. Other side effects were more substantial with higher doses, however, including two of 11 patients with hallucinations and confusion. In summary, adjunctive single- daily-dose cabergoline therapy resulted in long-lasting, dose-related improvement in parkinsonism not seen in patients receiving placebo.

KW - Cabergoline

KW - Dopamine agonists

KW - Ergolines

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=0029940040&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029940040&partnerID=8YFLogxK

M3 - Article

C2 - 8726539

AN - SCOPUS:0029940040

VL - 19

SP - 202

EP - 212

JO - Clinical Neuropharmacology

JF - Clinical Neuropharmacology

SN - 0362-5664

IS - 3

ER -